NCT03727633 2026-03-31
LIDA-BII
University Hospital, Montpellier
Phase 2 Terminated
Clinical Trials
8 trialsNCT03860844 2025-09-09
ISAKIDS
Sanofi
Phase 2 Terminated
NCT01607645 2017-03-31
Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT00528450 2016-01-29
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT00096148 2013-01-24
Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00023920 2013-01-23
Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00003729 2012-09-24
Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic Leukemia
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT00210366 2010-07-30
Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Terminated